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This review summarizes the studies on the cognitive side-effects of two important antiepileptic drugs: pheny- 
toin and carbamazepine. A large literature database was compiled through the DIMDI computer database and 
the inspection of recent reviews. Only scientific articles published in peer-reviewed journals during the last 25 
years were selected. Of the 358 potentially relevant papers on cognitive ffects of AEDs, a total of 16 studies 
have been found that have studied both carbamazepine and phenytoin. After excluding studies with designs 
that do not permit valid inferences regarding the cognitive ffects of AEDs, only five studies remained. 
The evaluation of these studies reveal that our current knowledge allows us to draw conclusions about he 
cognitive side-effects of phenytoin and carbamazepine only with great caution. The claim in reviews that 1~oth 
drugs have an impact on cognitive function, PHT to a larger degree than CBZ' is simply not supported by valid 
'high quality' data. The same is true for the overall conclusion in more recent reviews that 'drug-induced 
cognitive ffects of these AEDs on cognitive function are probably mild or even negligible'. Apparently, the 
only information that we have is that the differential impact of PHT and CBZ on cognitive function is not 
extremely different. No conclusive and reconfirmed ata are available on the absolute ffects of CBZ and PHT 
(differences between the two drugs and a no-treatment condition). 
Our review summarizes some recommendations for future studies. 
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INTRODUCTION 
During the last 25 years, a considerable 
number of studies has been published on the 
topic of cognitive side-effects of antiepileptic 
drugs (AEDs). At first glance these cognitive 
side-effects seem less dramatic than e.g. the 
acute dose-related effects or the idiosyncratic 
reactions to drugs. Nonetheless, a number of 
studies have claimed that drug-induced cogni- 
tive impairment may have a much greater 
impact on daily life function than had hitherto 
been suspected 1-9. 
The cognitive side-effects represent the long- 
term outcome of the chronic toxicity of the 
AEDs rather than the acute reaction to drugs. 
This may contribute to the impact on daily life 
functioning, especially in refractory epilepsies, 
as the effects may increase with prolonged 
therapy l°. 
As a consequence, cognitive side-effects now 
represent a major issue in clinical assessment 
and in studies on new antiepileptic drugs. For- 
tunate as this is, the literature still shows 
serious controversies about type and severity 
of drug-induced cognitive impairment, even in 
recent and well-controlled studies. These con- 
troversies are due to e.g. differences between 
the studies with respect o the type of subjects 
investigated and the design used to detect he 
drug effects. 
In this review we will concentrate on two 
most commonly used (and studied) AEDs phe- 
nytoin (PHT) and carbamazepine (CBZ). While 
evaluating the reports on PHT and CBZ, and 
their conflicting results, we will consider 
certain basic methodological issues with 
general implications for the assessment of 
drug-induced cognitive impairment. 
Phenytoin was first introduced for treatment 
in 1938 and was long (together with phenobar- 
bitone) the universal treatment for epilepsy. 
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Carbamazepine was not introduced until the 
1960s, although the drug was used as an anti- 
depressant at an earlier stage. The structure is 
similar to other tricyclic antidepressants. In 
contrast with PHT the administration of CBZ 
is mostly in multiple dose form TM 12 
One of the most authoritative reviews of the 
recent years 2 gave the following table (Table 
1), summarizing the results of a large number 
of studies on effects of several AEDs on general 
behaviour and on cognitive function. The 
suggestion from this summary, but also from 
other reviews 1-9' lo. 12,14 is clearly that PHT is 
more harmful to cognitive function than CBZ. 
Table 1 : Summary of the effects of anticonvulsants on 
cognitive function and behaviour 
Behaviour Cognitive function 
Carbamazepine Minimal Minimal 
Clonazepam Impairs Impairs 
Ethosuximide ~ 
Phenobarbitone Impairs Minimal 
Phenytoin Minimal Impairs 
Sodium Valproate Minimal ? 
Source: Trimble, 1987, p. 141. 
This conclusion came back into debate 
recently as some studies ls-19 failed to repro- 
duce the cognitive side-effects of PHT when 
serum concentrations were sufficiently con- 
trolled. These studies suggest hat some of the 
reported differences between CBZ and PHT 
actually may have been due to an artefact, i.e. 
differences in drug concentration. Moreover, 
some studies suggested that subject selection 
bias may have influenced the results, as there 
is evidence that, at least in some countries, 
phenytoin may be given to other types of 
patients than carbamazepine. PHT is cheaper 
and it is considered a 'simple drug', because it 
can be given once a day 14'2°-23. Observed cog- 
nitive differences between groups after ex- 
posure to PHT and CBZ may thus simply 
reflect prior differences rather than drug 
effects. This implies that a baseline-measure- 
ment is crucial to reach valid conclusions about 
drug effects, at least in studies where random- 
ized treatment allocation is not feasible. 
Finally it is suggested that the apparent 
adverse effects of PHT on cognitive functions 
may actually have been due to a contaminat- 
ing factor: motor speed. In one study 19 motor 
slowing appeared to be the only factor that dis- 
criminated between PHT and CBZ. As almost 
all cognitive tests use motor output, 'periph- 
A.P. Aldenkamp & J. Vermeulen 
eral' motor effects may erroneously have been 
interpreted as 'central', cognitive ffects. 
A critical review of the existing literature on 
PHT-CBZ comparisons i therefore useful, both 
for future research and for the proper in- 
terpretation of existing data, a highly relevant 
issue to clinical practice. 
IDENTIFICATION OF RELEVANT STUDIES 
Literature-search 
As a first step in identifying relevant studies, 
the DIMDI computer-database was accessed 
through the keywords AEDs and antiepileptic 
drugs. Next, a number of rev iews  1-14'2°-23 on 
the same topic were checked for additional 
references. These papers were screened for 
information about cognitive side-effects of 
AEDs. The resulting literature base comprised 
358 potentially relevant papers. Then the 
inclusion criteria given in Table 2 were 
applied. 
Table 2: Literature selection: inclusion and exclusion criteria 
1. Type of article: report of original research, in 
English, in peer reviewed journals or 
proceedings, published after 1970. 
Excluded: reviews, abstracts, brief 
communications, internal journals of the 
pharmaceutical industry. 
2. Subjects: epilepsy or healthy volunteers. 
Excluded: psychiatric patients, delinquents, 
mentally handicapped, children with behavioural 
or mood problems, animal studies. 
3. Treatments: current AEDs. 
Excluded: studies on experimental drugs that 
have failed to prove efficacy and will not be 
introduced in clinical practice, such as flunarizine 
or loreclezole. 
4. Outcome measures: psychometrically assessed 
cognitive functions. 
Excluded: clinical observations, studies employing 
complaint indices. 
These criteria reflect both our clinical and 
theoretical interest. Included studies should be 
readily accessible, and allow the readers to 
judge the validity of the results; abstracts, for 
example, usually do not provide sufficient 
detail. The target population is the epilepsy 
patient, receiving long-term AED treatment. 
AED treatment in other groups is associated 
with complicating interactions between con- 
dition and therapy. An exception was made for 
studies in healthy volunteers, on the assump- 
tion that such studies might suggest hypoth- 
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eses worth further exploration in epilepsy. The 
constraint on publication date was set fairly 
arbitrarily at 25 years ago. Studies after that 
date were all done in a time when serum level 
monitoring and modern cognitive tests had 
come into widespread use. After application of 
these criteria, a database of 73 articles re- 
mained. A review of this database will be pre- 
sented elsewhere. A last criterion was that 
only those studies were included that exam- 
ined both PHT and CBZ within the same 
investigation. This criterion was formulated 
because of the large variation between studies 
with respect o type of cognitive tests, number 
of tests and the 'cognitive models' to interpret 
the test results. To guarantee comparability of
results, inclusion of a study only followed when 
both type of AEDs were examined with the 
same set of tests. After application of these cri- 
teria, a database of 16 articles 15-17"24-:~7 re- 
mained. 
In weighing the evidence from these studies, 
the approach taken here is primarily to evalu- 
ate their design and analysis, disregarding 
studies that contain certain basic deficiencies 
that render them uninformative with regard to 
cognitive AED effects, because they fail to rule 
out too many plausible alternative expla- 
nations. The emphasis in this review on 
aspects of methodology is due, as some designs 
are arguably not sufficient for permitting 
reasonably valid inferences regarding the cog- 
nitive AED-effects. The problems examined 
here are not minor annoyances: their impact 
on the validity of the conclusions drawn is such 
that a useful AED, not harmful to cognitive 
functioning might look bad, while genuine 
adverse cognitive ffects might be missed. 
One example may illustrate the relevance of 
methodological nd statistical issue. Authors 
may wish to emphasize 'no effect' findings, par- 
ticularly if these are in line with the research 
hypothesis that a certain AED has no adverse 
cognitive ffects. In contrast to studies in other 
areas, non-significant results are seen as good 
news here as they represent the absence of cog- 
nitive side-effects. This conclusion lacks mean- 
ing, however, unless the a-priori probability of 
obtaining a significant result ('the power') is 
sufficiently high (80c~ being a conventional 
value). In other words, the study should have 
been able to detect genuine impairment and 
non-significance should not be due to insuf- 
ficient power. The power decreases especially if
small samples are used, or if the effect size, i.e. 
the magnitude of the cognitive effects under 
study, is small. In order to achieve an 80c~ 
chance of detecting small, medium and large 
differences {0.20, 0.50 and 0.80 standard- 
deviation, respectively in line with the con- 
vention proposed by Cohen :~s) between two 
independent means, the necessary number of 
patients per group, at a 5e;~ significance level, 
is 393, 64 and 26, respectively. Nonetheless, 
limited sample sizes (20 or lessl are used in the 
majority of studies {column 3 in Tables 3 and 
41. By consequence, these studies can only 
detect cognitive ffects of such magnitude that 
they would presumably be obvious to the clin- 
ician, even without psychological tests. And 
yet, conclusions that state a 'no effect' are 
readily found in literature, even in low- 
powered studies with a minimal chance of find- 
ing anything but unrealistic massive effects. 
With 'no-effect' claims it is therefore worth 
checking whether they might not simply 
reflect inadequate power. Thus, the studies 
published in this field are first examined with 
respect to formal characteristics relevant to 
valid inference making about cognitive side- 
effects. With only high quality data to go on, 
the last section of this review attempts to draw 
conclusions in which some confidence can be 
placed. 
DESCRIPTION OF THE INVESTIGATED 
STUDIES 
Tables 3 and 4 give a general summary of 
studies that were found in our literature 
search on cognitive side-effects of CBZ and 
PHT. 
The studies will be summarized in Tables 3 
and 4 in terms of five relevant features: ( 11 the 
treatments under comparison; (21 the n umber of 
subjects In) in each treatment condition, 
including untreated controls; I31 the drop-out 
rate that gives an indication as to whether a 
selection artifact might have developed uring 
the trial; (4) the number of cognitive variables 
used as outcome measures, that gives an indi- 
cation of the possible scope of the study with 
respect to cognitive functioning; (5) the time on 
AEDs under study is an important consider- 
ation in judging to what extent the results 
apply to chronic AED use. 
Study 1 
The first study 16 mentioned in Table 3 is the 
only normal-volunteer study in which CBZ and 
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Table 3: Studies that do not allow inferences about cognitive side-effects (PHT/CBZ period 1970-1994) 
Treatments* Subjects ( n ) Drop-out Cognitive Time on 
on AEDs untreated rate tests (n) AEDt 
controls$ 
Type of study 
I. Normal  vo lunteer  studies 
1. Meador et al., 1991 
2. Ep i lepsy-stud ies  
a. Po ly therapy  studies  
2. McKee et al., 1994 
PHT/CBZ 21 - -  30q 20 1 month 
PHT/CBZ/ 
VPA+(OXC/plac)/ 
OXC 
9/9/10/7 - -  19c~ 8 8 weeks 
b. Monotherapy  studies  prov id ing  insuff ic ient  in format ion for evaluat ion 
3. Marchesi et al., 1980 PHT/CBZ/PHB 10/10/6 ? ~ 
4. Butlin et al., 1984a PHT/CBZ/VPA ? ~ ? 
5. Smith et al., 1987 PHT/CBZ/PHB/PRI ? 75 9 ? 
c. Monotherapy  studies with post-test  on ly  des igns 
6. Butlin et al., 1984b PHT/CBZ/VPA 57/34/25 - -  n.a. ? 
7. Andrewes et al., 1986 PHT/CBZ 21/21 21E n.a. 30 
8. Brodie et al., 1987 PHT/CBZ/VPA 15/30/9 14E/11 n.a. 9 
9. Gillham et al., 1990 PHT/CBZ/VPA 19/35/30 26E/24 n.a. 12 
10. Bittencourt et al., 1992 PHT/CBZ/VPA 7/16/8 35 n.a. 5 
>1 month 
3 months 
12 months? 
9 
5.8/3.6 years 
>3 months 
>3months 
>1 year 
* plac = placebo. Individual AEDs are in bold print: CBZ = carbamazepine; OXC = oxcarbazepine; PHT = phenytoin; 
VPA = valproate; PHB = phenobarbital; PRI  = primidon. 
This refers to the duration of the experimentally changed AED treatment c.q., the continuous medication interval studied, 
or the duration of AED therapy prior to assessment in cross-sectional studies. 
:~ E denotes epileptic ontrols; other controls are non-epileptic controls. 
n.a. = not applicable; ? = information insufficient, ambiguous or lacking. 
Table 4: Studies on cognitive side-efects of PHT vs CBZ (monotherapy studies in epileptic patients; period 1970-1994) 
Treatments': Subjects (n I Drop-out Cognitive Time on 
on AEDs untreated rate tests (n I AED¢ 
controls 
Type of study 
d. Monotherapy  studies  with acceptable  des igns and  insuf f ic ient  in format ion 
11. Gallassi et al., 1992 PHT/CBZ/PHB/ 27/18/16 28 +40q 
12. Gallassi el al., 1988 
13. Aldenkamp et al., 1993 
14. Dodrill and Troupin, 1977 
15. Aikiae et al., 1992 
16. Meador et al., 1990 
10 21monthst 
VPA 
PHT/CBZ 12/13 26 ~ 13 21 monthst 
PHT/CBZ/VPA 56/17/10 83 17q 12 7 months$ 
PHT/CBZ 40 - -  + 2q 24 8 months 
PHT/CBZ(OXC) 14/15 - -  20q 7 6/12 months 
PHT/CBZ/PHB 15 - -  +28q 7 9 months 
*plac = placebo. Individual AEDs are in bold print: CBZ = carbamazepine; OXC = oxcarbazepine; PHT = phenytoin; 
VPA = valproate; PHB = phenobarbital. 
t This refers to the duration of the experimentally changed AED treatment c.q., the continuous medication interval studied, 
or the duration of AED therapy prior to asessment in cross-sectional studies. 
$ In the withdrawal studies the period refers to the total follow-up period (withdrawal of the drug and follow-up after 
withdrawal}. 
? = Information insufficient, ambiguous or lacking. 
PHT  was  s tud ied .  CBZ and  PHT is g iven  
dur ing  a month  to normal  vo lunteers  in  a ran -  
domized  c ross -over  des ign .  
A few comments  have  to be  made when 
assess ing  the  va lue  of  the  resu l t s  o f  any  
normal -vo lunteer  s tudy  on cogn i t ive  e f fects  of  
AEDs .  Th is  type  of  s tudy  has  some c lear  
advantages .  The  prob lems of  the  in terven ing  
cont r ibut ion  o f  se i zure - re la ted  var iab les  on 
cogn i t ive  funct ion  is absent  and  man ipu la t ions  
of  d rug  and  dose  are  not  l im i ted  by  c l in i ca l  
cons iderat ions .  A c lear  d i sadvantage  is that  
the  per iod  o f  d rug  exposure  is most ly  res t r i c -  
ted.  There  is ev idence  that  in  most  AEDs  some 
'ear ly '  cogn i t ive  s ide -e f fec ts  may deve lop ,  on ly  
dur ing  a shor t  per iod ,  i.e. dur ing  the  f i rs t  few 
days  or  weeks  of  d rug  exposure .  A f te r  th i s  
per iod  normal i za t ion  occurs ,  poss ib ly  due  to 
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the development of so-called positive toler- 
ance 39. Although little is known about how 
tolerance to the cognitive effects of AEDs de- 
velops, a failure to control the period of drug 
exposure may lead to overestimation of the 
negative ffects of drugs on cognition 2°'2~. This 
important point has to be taken into account in 
studies with healthy volunteers who are typi- 
cally given AEDs during a few weeks at most, 
long-term studies not being feasible. 
Our examination of the 14 normal-volunteer 
studies that were carried out to assess the cogni- 
tive effects of AEDs revealed that the majority 
of these studies used a fairly short period of drug 
exposure, often no longer than 1 day. The study 
by Meador et al. 16 is an exception as both AEDs 
were given during a period of one month. 
Study 2 
In total we found 20 polytherapy studies on cog- 
nitive effects of AEDs. Only one study 36 met 
our criterion that the study should investigate 
both PHT and CBZ. Polytherapy is the most 
common treatment in refractory epilepsies but 
it introduces certain complications in identify- 
ing the exact cause of observed cognitive 
changes. Interactions between antiepileptic 
drugs became evident soon after routine 
measurement of serum levels came into prac- 
tice. Such interactions can alter therapeutic 
efficacy and thus, conceivably, cognitive func- 
tioning. Moreover polytherapy is typically 
given to patients uffering from refractory epi- 
lepsy, and the threat of a 'seizure confound' is 
thus always serious. 'Seizure confound' refers 
to a major validity concern: the separation of 
seizure effects from 'genuine' AED-effects. 
The study by McKee et al. 36 is an 'add-on 
study', where a new drug is introduced into a 
polytherapy regime. In this type of study the 
seizure confound is even stronger and the 
results on cognitive tests are a potpourri of 
positive and negative seizure effects, AED- 
effects and drug-drug interactions that can 
never be disentangled. It is therefore imposs- 
ible to use this type of study for inferences 
about differential-cognitive side-effects of 
PHT/CBZ. 
Studies 3-5 
The studies numbered 3-5 in Table 3 are com- 
bined under the heading 'monotherapy studies 
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providing insufficient information for evalu- 
ation '17"29"35. This illustrates an important 
point that we want to make here. Some papers 
evidently do not provide the information to 
enable the reader to evaluate the appropriate- 
ness of the methods and the reliability and val- 
idity of the results. For example, certain 
articles fail to give the number of subjects 
studied, do not report inferential statistics to 
support he conclusions, or mention only those 
cognitive variables yielding significant effects. 
One is thus forced into the unfortunate pos- 
ition of either accepting results uncritically, or 
specifying certain minima with respect o the 
methodological/statistical information pro- 
vided, that must be met before evaluation is 
possible. We chose the latter option. In this 
review we employ only the criteria: 'numbers 
of patients' and 'number of cognitive variables'. 
Evidently, these data are essential to evaluate 
the statistical power of the study and, conse- 
quently, the validity of the reported results, 
especially in the case of 'no-effect' reports. All 
three studies, mentioned under this heading in 
Table 317'29'35 fail to meet these presentation 
minima and are thus considered elusive to 
evaluation due to insufficient information. 
Studies 6-10 
The studies, numbered 6-10 in Table 
326-2s'3°'34 are monotherapy studies that have 
a specific design in common, the post-test-only 
design, that also needs some general 
comments. Due to the lack of pretest obser- 
vations in this 'one-shot case design' there is no 
way of knowing whether the treatment is 
related to any kind of cognitive change. Post- 
test differences can be attributed either to a 
treatment effect or to various selection differ- 
ences between PHT/CBZ groups. The plausi- 
bility of such selection differences renders this 
design uninterpretable. Note that it is a differ- 
ent matter with randomized experiments 
where pretests can be dispensed with, random 
assignment insuring the comparability of the 
treatment groups. In a post-test-only design 
without random treatment allocation, one can 
never be certain that some variable that has 
been overlooked will not bias the outcome of 
the study. Control on selection bias is thus 
essential in any non-randomized study and can 
only be achieved by using a pre- and post-test 
design. 
A concrete example of a validity threat in 
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this design is found in the study by Andrewes 
et al. 26 The authors conclude that PHT shows 
an overall trend towards poorer performance 
on several cognitive tasks when compared to 
CBZ. This study is frequently cited as evidence 
for the cognitive side-effects of PHT. However, 
as Table 3 shows, the period of drug exposure is 
different between the two groups (3.6 years for 
CBZ and 5.8 years for PHT). It is conceivable 
that longer drug exposure in itself, regardless 
of type of drug, leads to the differences between 
the investigated groups. Thus, the results of 
such studies do not allow valid inferences 
about cognitive side-effects of AEDs as their 
design is generally uninterpretable 4°. 
The monotherapy studies numbered 11-16 
in Table 415'24"25'31-33 potentially allow valid 
inferences about the cognitive effects of PHT 
and CBZ. At least they meet the minimal re- 
quirements that were formulated in the fore- 
going: 
- -  a period of drug exposure that allows the 
generalization ofthe results to the 'regular' 
epilepsy patient on long-term AED therapy; 
- -  minimal standards for presentation of the 
results; 
- -  a design that allows us to distinguish the 
cognitive ffects of AEDs from factors such 
as selection bias (thus excluding the post- 
test-only design); 
- -  a type of treatment that allows interpret- 
ation of specific effects of PHT and CBZ 
(thus excluding polytherapy studies). 
Seven studies meet these criteria. However, 
some of these studies have such problems in 
design and analysis that inferences about cog- 
nitive side-effects of AEDs are impossible, if 
only because alternative xplanations cannot 
be ruled out. We do not intend to give a com- 
plete description of these studies, but merely 
comment on the factors that prevent he in- 
terpretation ofthe study results. 
practice ffect. Thus, the validity of the results 
from this type of study largely depends on the 
extent o which retesting effects are controlled. 
Retesting effects are dependent on factors uch 
as the type of tests and the number of retests. 
Gallassi and coworkers use four retests and at 
least three of the tests are known to be ex- 
tremely sensitive to such retesting effects: 
'Raven Progressive Matrices', a Visuo-Motor 
Test and a Verbal Learning Task. Apparent 
improvement produced by retesting may thus 
erroneously be interpreted as evidence for the 
elimination of cognitive side-effects. In the 
Gallassi studies a'~'~3, however, the control sub- 
jects are only tested once. Thus it would not be 
clear whether any differences between groups 
were due to the removal of the treatment or to 
differences in the frequency of measurement. 
Study 13 
The Swedish 'Holmfr id study "~ also uses a 
withdrawal design: assessing patients on 
monotherapy PHT or CBZ, followed by re- 
assessment after complete withdrawal of the 
medication. Practice effects are controlled by 
the use of a control group that follows the same 
testing schedule as the experimental groups. 
Study 14 
One of the pioneer studies in this field is the 
study by Dodri l l  and Troupin 3~ comparing 
CBZ with PHT in a randomized cross-over 
design. Patients are assessed at the end of a 
four-month treatment period. The study gives 
data on relative effects of the drugs, i.e. differ- 
ences between PHT and CBZ. The patients 
have not been tested pre-treatment or com- 
pared to an untreated control group. 
Studies 11 and 12 
The studies by Gallassi and coworkers "J'2":33 use 
an interesting design: patients are tested on 
monotherapy and retested after removal of the 
medication. The assumption in this 'with- 
drawal design' is that reversible side-effects 
are demonstrated by an improvement after a 
drug is stopped. A point to be made here is that 
other factors can also cause such improvement, 
one of the most obvious being the retesting or 
Study 15 
The study by Aik ia  et al. 24 uses a randomized 
double-blind parallel group design. Patients 
are assessed before the treatment is started, 
and then given either of the two AEDs. The 
study does not use carbamazepine but the 
related rug oxcarbazepine. The absence of the 
metabolite poxide m'~ in oxcarbazepine, that 
may possibly cause the side-effects in car- 
bamazepine treatment, may reduce the gener- 
alizability of the results towards ordinary 
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Table 5: Summary of the demonstrated cognitive side-effects of phentyoin and carbamazepine 
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Relative drug effects: Absolute drug effects: 
differences between PHT and CBZ differences between PHT/CBZ and a 
non-drug condition 
1. Meador et al., 1991 
2. Dodrill and Troupin, 1977 
3. Aikiae el al., 1992 
4. AIdenkamp et al., 1993 
5. Meador et al., 1990 
No extreme differences 
No extreme differences 
Inconclusive 
Inconclusive 
No extreme differences 
Inconclusive 
Not assessed 
Inconclusive 
No differences between CBZ and a 
non-drug condition 
Not assessed 
carbamazepine treatment. Other limitations of 
this study will be discussed in the next para- 
graph. 
Study 16 
The study by Meador et al. 5 is a randomized 
double-blind triple cross-over design compar- 
ing CBZ with PHT and PHB in 15 patients. 
The study lacks a no-treatment reference: the 
patients are not tested during a pretreatment 
phase and the study does not use an untreated 
control group. 
Of these studies, the two Gallassi 
studies 32'33 have such serious threats to val- 
idity that the results can not be safely inter- 
preted. The results of the remaining studies 
plus the normal volunteer study ~6 are dis- 
cussed in detail in the next section. 
RESULTS OF THE INVESTIGATED STUDIES: 
INFERENCES ABOUT THE COGNITIVE SIDE- 
EFFECTS OF PHENYTOIN VS 
CARBAMAZEPINE 
In this section we summarize the results of 
those studies that do allow interpretation of 
the data. Table 5 summarises these studies. 
Study 1 
In the normal volunteer study ~6, two of the 20 
drug-drug comparisons between PHT and 
CBZ yielded statistical significance: Finger 
tapping favoured CBZ and Stroop favoured 
PHT. However, as the study used separate F- 
tests, this may well represent a chance finding, 
a point that is recognized by the authors. 
This illustrates a more general issue. In 
most studies multiple measures are used to 
capture cognitive AED effects, and then tested 
independently for significance. However, the 
probability of falsely concluding that one or 
more significant effects exist, increases as a 
function of the number of statistical tests per- 
formed, and a certain proportion of the tests 
will be significant by chance. Thus, with a con- 
ventional 5% significance level, one may 
expect that 1 in 20 cognitive measures will 
yield a significant effect by chance alone. Fail- 
ure to recognize this problem may lead to 'fish- 
ing' for significant findings, some of which may 
be 'false positives', whereas measures failing to 
yield significant effects may not even be men- 
tioned as having been administered '7°. 
The comparison of CBZ or PHT with a 'non- 
drug condition' raises a problem regarding the 
validity of their conclusion that 'no differences 
exist between the two drugs and the non-drug 
condition'. The study does not employ an 
untreated control group but uses two non-drug 
conditions: the subjects are tested at baseline 
(before the first drug is given) and after treat- 
ment and withdrawal of the second drug. The 
scores of the two non-drug conditions are then 
averaged; this score is compared with the two 
drug conditions. This procedure may over- or 
under-estimate drug-effects, as the second 
baseline is the fourth consecutive measure- 
ment and is thus maximal biased by retesting 
effects conceivably leading to exaggerated non- 
drug scores. On the other hand, the study is not 
conclusive as to whether both drug conditions 
(second and third assessment) are also affected 
by retesting effects. Only an independent non- 
drug group, tested and retested at the same 
intervals could have controlled for these retest- 
ing effects. 
We must therefore conclude that this study 
only gives interpretable data as far as the 
drug-drug comparison is involved. This com- 
parison did not yield significant differences be- 
tween PHT and CBZ above chance level. As the 
number of subjects in this study is rather small 
(n = 21), this 'no difference' finding is not par- 
ticularly meaningful without a formal power 
analysis, showing that even small or medium 
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sized effects could have been detected. At best 
we may infer from these results that massive 
differences were not present. 
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of this study, causing a failure to detect 
genuine impairment. We therefore evaluate 
the evidence from this study as inconclusive. 
Study 2 
In the original study by Dodrill and Troupin ~' 
impairment of attention and problem solving 
in PHT (relative to CBZ) was reported, but 14 
years later the authors reanalysed their data TM 
and argued that no differences between PHT 
and CBZ remained, after removing high PHT 
serum levels. This procedure of course resulted 
in smaller sample sizes, i.e. when removing 
patients with serum levels >40~tg/ml, the 
sample size decreased from 40 to 29, with the 
removal of serum levels >30 ~xg/ml, a sample of 
15 patients remained. The original statistical 
differences were lost with these smaller sample 
sizes. A formal power analysis to support the 
meaning of this no-difference (true absence of 
differences, or an effect of insufficient power} 
was not presented. Again, at best, we may infer 
from these results that extreme differences be- 
tween PHT and CBZ were probably not 
present. 
Study 3 
The study by Aikia et al.  24 seems to reconfirm 
the absence of differences between the PHT 
and CBZ in a different patient group (seizure- 
free patients vs refractory patients in the 
former study by Dodrill and Troupin) with 
PHT serum levels of about 50% lower than in 
the study by Dodrill and Troupin. The study 
reports both the absence of PHT-CBZ differ- 
ences and drug-non drug differences, suggest- 
ing a complete absence of cognitive drug 
effects. 
We have pointed out in the foregoing that 
the results of this study must be interpreted 
with caution as the study does not compare 
phenytoin with carbamazepine but with the 
related drug, oxcarbazepine. An additional 
problem is the limited sample size (14 vs 15), 
combined with a 20% drop-out rate in this 
study. An example of the effect of the small 
sample size is that even a difference between 
the groups of approximately one standard- 
deviation at pretest (an effect size that is gen- 
erally considered as 'large 'as} still does not 
yield statistical significance. Thus the absence 
of effects may simply reflect the limited power 
Study 4 
The Swedish withdrawal study 25 reported no 
significant differences between CBZ and PHT 
in children. In addition, no differences were 
found with untreated controls in both con- 
ditions (during treatment and after with- 
drawal}. This suggests the absence of cognitive 
effects of both PHT and CBZ. 
However, the group of patients on phenytoin 
is probably too small to render a sufficient level 
of statistical power (n -- 10). Valid comparisons 
between PHT and CBZ and between PHT and a 
non-drug condition are therefore not possible. 
The data only allows valid inferences about 
differences between CBZ (n = 56) and the non- 
drug condition (n = 83). This comparison does 
not yield significant differences. 
Study 5 
The final study that will be discussed here is 
the study by Meador et al .  15 The study com- 
pares the cognitive effects of PHT with CBZ 
but lacks an absolute reference: the patients 
are not tested uring a pretreatment phase and 
the study does not use placebo control or an 
untreated control group. The overall con- 
clusion of the study, i.e. 'no differences between 
the drugs' can only be given limited credit. The 
study uses a small sample (15 patients; seven 
cognitive variables} that only allows to detect 
massive cognitive changes. 
CONCLUSIONS 
A disappointing number of studies pass cri- 
teria of design, methodology and statistical 
analysis that are in line with common scien- 
tific conventions 4°. From a database of 358 
papers on cognitive effects of AEDs, a total of 
16 studies have been found that have studied 
both CBZ and PHT. After the exclusion of the 
polytherapy studies, post-test only studies as 
well as studies that could not be evaluated 
because of the lack of information, only seven 
studies remained of which five studies poten- 
tially allowed valid inferences about the cogni- 
tive effects of PHT and CBZ. This necessarily 
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leads us to our first conclusion: our current 
knowledge about these side-effects i far from 
complete. The main reason is that most studies 
fail to meet the criteria for design, method- 
ology and type of analysis that are indis- 
pensable for the rather complex studies on 
cognitive ffects of AEDs. 
Our current knowledge allows us to draw 
conclusions about the cognitive side-effects of 
phenytoin and carbamazepine only with great 
caution. The summaries that were shown in 
the introduction and that by and large claim 
that 'both drugs have an impact on cognitive 
function, PHT to a larger degree than CBZ ''~ 
are simply not supported by valid 'high quality' 
data. The same is true for the overall con- 
clusion in more recent rev iews  14'2°'21 that 
'drug-induced cognitive effects of these AEDs 
on cognitive function are probably mild or even 
negligible'. Table 5 does neither support the 
first nor the second overall conclusion but 
rather illustrates a surprising lack of knowl- 
edge. 
There are three studies that claim evidence 
that the differences between PHT and CBZ are 
probably mild or even absent. These studies 
presumably lack statistical power (given the 
small sample sizes) and may thus have missed 
genuine impairment. Apparently, the only 
information that we have is that the differen- 
tial impact of PHT and CBZ on cognitive func- 
tion is not extremely different. 
Furthermore, the absence of PHT-CBZ 
differences obviously does not rule out the 
possibility that they are not different because 
they both impair cognitive function to the same 
extent. This of course is crucial for clinical 
practice, especially in the light of the new gen- 
eration of antiepileptic drugs that are or will 
be marketed in the near future. AEDs such as 
felbamate, tiagabine, lamotrigine, oxcarbaze- 
pine or the new experimental drugs, such as 
CGP 33.101, gabapentin or topiramate, might 
be good alternatives when they have the same 
efficacy, but with fewer side-effects. Regret- 
tably no conclusive and reconfirmed ata are 
available on PHT and CBZ. This implies that 
we have no ready advice for the clinician. 
Rather we have to encourage research pro- 
grammes that investigate these AEDs with a 
more solid design, and simultaneously screen 
the new compounds according to the same 
standards. 
For future studies we would strongly recom- 
mend that cognitive ffects of AEDs would be 
investigated: 
- -  only under monotherapy; 
- - w h e n  randomized treatment allocation is 
not feasible, with a pre- and post-test com- 
parison; 
- -  with a non-drug condition. Which condition 
needs to be used (placebo, pretreatment 
assessment or a non-drug control group) 
depends upon the type of study; 
- -  after a prospective power analysis to deter- 
mine the necessary sample size for the 
study to make valid 'no-effect' inferences 
about specific AEDs. 
Other more detailed conditions have been 
summarized elsewhere L4.z°'2~'~'~ 
REFERENCES 
1. Trimble, M.R. Anticonvulsant drugs and psychosocial 
development: phenobarbitone, sodium valproate, and 
benzodiazepines. In: Antiepileptiv Drug Therapy in 
Pediatrics [Eds P.L. Morselli, C.E. Pippenger and J.K. 
Penry). New York, Raven Press, 1983: pp. 201-217. 
2. Trimble, M.R. Anticonvulsant drugs: mood and cogni- 
tive function. In: Epilepsy. Behaviour and Cognitive 
Function (Eds M.R. Trimble and E.H. Reynolds). 
Chichester, John Wiley & Sons, 1987: pp. 135-145. 
3. Trimble, M.R. Anticonvulsant drugs and cognitive 
function: a review of the literature. Epilepsia 1987: 
28($3): S37-S45. 
4. Trimble, M.R. and Thompson, P.J. Memory, anticon- 
vulsant drugs and seizures. Acta Neurologico Scandi- 
navica 1981; 64: 31-41. 
5. Trimble, M.R. and Thompson, P.J. Anticonvulsant 
drugs, cognitive function and behaviour. Epilepsia 
1983; 24(Suppl. 1 ): $55-$63. 
6. Trimble, M.R. and Thompson, P.J. Sodium valproate 
and cognitive function. Epilepsia 1984: 25(SD: 60-64. 
7. Trimble, M.R. and Thompson, P.J. Anticonvulsant 
drugs, cognitive function and behaviour. In: Paediatric 
Perspectives on Epilepsy I Eds E. Ross and E. Reynolds). 
Chichester, John Wiley & Sons, 1985: pp. 141-148. 
8. Trimble, M.R. and Cull, C. Children of school age: the 
influence of antiepileptic drugs on behavior and intel- 
lect. Epilepsia 1988; 29(Suppl. 3~: S15-S19. 
9. Trimble, M.R., Thompson, P.J. and Huppert, F. Anti- 
convulsant drugs and cognitive abilities. In: Advances 
in Epileptology (Eds R. Canger, F. Angeleri and J.K. 
PenryL New York, Raven Press, 1980: pp. 199-204. 
10. Committee on Drugs. Behavioral and cognitive ffects 
of anticonvulsant therapy. Pediatrics 1985; 76: 644- 
647. 
11. Evans, R.W. and Gualtieri, C.T. Carbamazepine: a 
neuropsychological and psychiatric profile. Clinical 
Neuropharmacology 1985; 8: 221-241. 
12. Parnas, J., Gram, L. and Flachs, H. Psychopharmaco- 
logical aspects of antiepileptic treatment. Progress in 
Neurobiology 1980; 15: 119-138. 
13. Parnas, J., Flachs, H. and Gram, L. Psychotropic effect 
of antiepileptic drugs. Acta Neurologica Scandinavica 
1979; 60: 329-343. 
14. Smith, D.B. Cognitive effects of antiepileptic drugs. 
Advances in Neurology 1991; 55: 197-212. 
104 
15. Meador, K.J.M., Loring, D.W., Huh, K., Calagher. B.B. 
and King, D.W. Comparative cognitive ffects of anti- 
convulsants. Neurology 1990; 40: 391-394. 
16. Meador. K.J.M., Loring, D.W., Allen, M.E., Zamriny, 
E.Y., Moore, E.E., Abney, O.L. and King, D.W. Com- 
parative cognitive ffects of carbamazepine and pheny- 
toin in healthy adults. Neurology 1991; 41: 1537-1540. 
17. Smith, D.B., Mattson, R.H., Cramer, J.A., Collins, J.F., 
Novelly, R.A. and Craft, B. Results of a nationwide 
Veterans Administration Cooperative Study compar- 
ing the efficacy and toxicity of carbamazepine, pheno- 
barbital, phenytoin, and primidone. Epilepsia 1987; 
28(Suppl. 3): $50-$58. 
18. Dodrill, C.B. and Troupin, A.S. Neuropsychological 
effects of carbamazepine and phenytoin; a reanalysis. 
Neurology 1991; 41: 141-143. 
19. Dodrill, C.B. and Temkin, N.R. Motor speed is a con- 
taminating factor in evaluating the 'cognitive' ffects 
of phenytoin. Epilepsia 1989; 30p: 453-457. 
20. Dodrill, C.B. Behavioral effects of antiepileptic drugs. 
Advances in Neurology 1991; 55: 213-224. 
21. Dodrill, C.B. Problems in the assessment of cognitive 
effects ofantiepileptic drugs. Epilepsia 1992; 33(Suppl. 
6): $29-$32. 
22. Wilder. B.J., Rangel, R.Y. Phenytoin; clinical use. In: 
Antiepileptic Drugs; Third Edition. (Eds R.H. Levy, 
F.E. Dreifuss. R.H. Mattson et al.) New York, Raven 
Press, 233-241. 
23. Novelly, R.A., Schwartz, M.M., Mattson, R.H. and 
Cramer, J.A. Behavioral toxicity associated with anti- 
epileptic drugs: concepts and methods of assessment. 
Epilepsia 1986; 27: 331-340. 
24. Aikiae, M., Kaelviaeinen, R., Sivenius, J., Halonen, T. 
and Riekkinen, P.J. Cognitive ffects ofoxcarbazepine 
and phenytoin monotherapy in newly diagnosed epi- 
lepsy: one year follow-up. Epilepsy, Research 1992; 11: 
199-203. 
25. Aldenkamp, A.P., Alpherts, W.C.J., Blennow, G., 
Elmqvist, D., Heijbel, J., Nilsson, H., Sandstedt, P., 
Tonnby, B., Wahlander, L. and Wosse, E. Withdrawal 
of antiepileptic medication--effects on cognitive func- 
tion in children--the r sults of the multicentre 'Holm- 
frid' study. Neurology 1993; 43: 41-51. 
26. Andrewes, D.G., Bullen, J.G., Tomliason, L., Elwes, 
R.D.C. and Reynolds, E. A comparative study of the 
cognitive ffects of phenytoin and carbamazepine in 
new referrals with epilepsy. Epilepsia 1986; 27: 128- 
134. 
27. Bittencourt, P.R., Mader, M.J., Bigarella, M.M., Doro, 
M.P., Gorz, A.M., Marcourakis, T.M. and Ferreira, Z.S. 
Cognitive functions, epileptic syndromes and antiepi- 
leptic drugs. Arquivos de Neuro-Psiquiatria 1992; 50: 
24-30. 
A.P. Aldenkamp & J. Vermeulen 
28. Brodie, M.J.. McPhail, E., Macphee. G.J.A., Larkin, 
J.G. and Gray, J.M.B. Psychomotor impairment and 
anticonvulsant therapy in adult epileptic patients. 
European Journal of Clinical Pharmacology 1987; 31: 
655-660. 
29. Butlin, A.T., Danta, G. and Cook, M.L. Anticonvul- 
sants, folic acid and memory dysfunction i epileptics. 
Clinical and Experimental Neurology 1984; 20: 57-62. 
30. Butlin, A.T., Danta, G. and Cook, M.L. Anticonvulsant 
effects on the memory peformance of epileptics. Clini- 
cal and Experimental Neurology 1984: 20: 37-35. 
31. Dodrill, C.B. and Troupin, A.S. Psychotropic effects of 
carbamazepine i  epilepsy: a double-blind comparison 
with phenytoin. Neurology 1977; 27: 1023-1028. 
32. Gallassi, R., Morreale, A., Lorusso, S., Procaccianti, G., 
Lugaresi, E. and Baruzzi, A. Carbamazepine and phe- 
nytoin. Comparison of cognitive ffects in epileptic 
patients during monotherapy and withdrawal. 
Archives of Neurology 1988; 45: 892-894. 
33. Gallassi, R., Morreale, A., Di Sarro, R., Marra, M., 
Lugaresi, E. and Baruzzi, A. Cognitive ffects of anti- 
epileptic drug discontinuation. Epilepsia 1992; 
33(Suppl. 6): $41-$44. 
34. Gillham, R.A., Williams, M., Weidmann, K.D., Butler, 
E., Larkin, J.G. and Brodie, M.J. Cognitive function in 
adult epileptic patients established on anticonvulsant 
monotherapy. Epilepsy Research 1990; 7: 219-225. 
35. Marchesi, G.F., Ladavas, E., Provinciali, L., Del Pesce, 
M., Fua, P. and Giuliani, G. Neuropsychological per- 
formances in patients treated with different antiepi- 
leptic drugs. Monographs in Neural Sciences 1980; 5: 
258-264. 
36. McKee, P.J.W., Blacklaw, J., Forrest, G., Gillham, 
R.A., Walker. S.M., Connelly, D., and Brodie, M.J. A 
double-blind placebo-controlled interaction study be- 
tween oxcarbazepine and carbamazepine, sodium val- 
proate and phenytoin in epileptic patients. British 
Journal of Clinical Pharmacology 1994; 37: 27-32. 
37. Smith, D.B. Anticonvulsants, seizures and perform- 
ance: the Veterans Administration experience. In: Epi- 
lepsy, Behaviour and Cognitive Function (Eds M.R. 
Trimble and E.H. Reynolds). Chichester, John Wiley & 
Sons, 1988: pp. 67-78. 
38. Cohen, J. Statistical Power Analysis for the Behavioral 
Sciences. New York, Academic Press, 1977. 
39. Kulig, B. and Meinardi, H. Effects of antiepileptic 
drugs on motor activity and learned behavior in the 
rat. In: Advances in Epileptology (Eds H. Meinardi and 
A.J. Rowan). Amsterdam, Swets & Zeitlinger, 1977: 
pp. 98-104. 
40. Cook, D. and Campbell, D.T. Quasi-Experimentation; 
Design & Analysis Issues for Field Settings. Boston, 
Houghton Mifflin Company, 1979. 
